Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APOB | P04114 | 1/20 | 0.47 |
| ▸ | MTTP | P55157 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492802 | 0.93 | POLB (0.47) | POLBTP53LMNAMAPTKIT | |
| SCHEMBL6501075 | 0.93 | RAB9A (0.43) | POLBTP53LMNAMAPTKDM4E | |
| SCHEMBL6497710 | 0.91 | POLB (0.49) | POLBAPOBMTTPTP53LMNA | |
| SCHEMBL6490142 | 0.90 | POLB (0.43) | POLBTP53LMNAMAPTKDM4E | |
| SCHEMBL6498339 | 0.88 | SMN1; SMN2 (0.51) | POLBAPOBMTTPTP53LMNA | |
| SCHEMBL6792997 | 0.88 | TP53 (0.49) | APOBMTTPTP53LMNAMAPT | |
| SCHEMBL6493011 | 0.86 | MTTP (0.48) | APOBMTTPTP53MCHR1KIT | |
| SCHEMBL6489328 | 0.86 | GCGR (0.42) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6488636 | 0.84 | APOB (0.48) | POLBAPOBMTTPTP53LMNA | |
| SCHEMBL6498250 | 0.84 | POLB (0.49) | POLBTP53LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | POLB 1626/4885APOB 1/4885MTTP 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.